Literature DB >> 33498803

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali.

Modibo Diarra1, Drissa Coulibaly1, Amadou Tapily1, Boureima Guindo1, Koualy Sanogo1, Diakalia Koné2, Youssouf Koné1, Karim Koné1, Aboudramane Bathily3, Oumar Yattara3, Mahamadou A Thera1, Alassane Dicko1, Abdoulaye A Djimdé1, Issaka Sagara1.   

Abstract

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization's standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (p < 0.001), and no serious events were recorded. Plasmodium falciparum remains sensitive to artemether-lumefantrine in Mali.

Entities:  

Keywords:  Mali; Plasmodium falciparum; artemether-lumefantrine; in vivo efficacy; malaria

Year:  2021        PMID： 33498803      PMCID： PMC7838931          DOI： 10.3390/tropicalmed6010013

Source DB:  PubMed          Journal:  Trop Med Infect Dis        ISSN： 2414-6366


  28 in total

1.  New WHO guidelines for the treatment of malaria.

Authors:  Hugh Reyburn
Journal:  BMJ       Date:  2010-05-28

Review 2.  Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.

Authors:  Valentine Duru; Benoit Witkowski; Didier Ménard
Journal:  Am J Trop Med Hyg       Date:  2016-10-17       Impact factor: 2.345

3.  In vivo parasitological measures of artemisinin susceptibility.

Authors:  Kasia Stepniewska; Elizabeth Ashley; Sue J Lee; Nicholas Anstey; Karen I Barnes; Tran Quang Binh; Umberto D'Alessandro; Nicholas P J Day; Peter J de Vries; Grant Dorsey; Jean-Paul Guthmann; Mayfong Mayxay; Paul N Newton; Piero Olliaro; Lyda Osorio; Ric N Price; Mark Rowland; Frank Smithuis; Walter R J Taylor; François Nosten; Nicholas J White
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

4.  Plasmodium falciparum: extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea.

Authors:  I Felger; L Tavul; S Kabintik; V Marshall; B Genton; M Alpers; H P Beck
Journal:  Exp Parasitol       Date:  1994-09       Impact factor: 2.011

5.  Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali.

Authors:  Halima Kaddouri; Abdoulaye Djimdé; Souleymane Dama; Aly Kodio; Mamadou Tekete; Véronique Hubert; Aminatou Koné; Hamma Maiga; Oumar Yattara; Bakary Fofana; Bakary Sidibe; Cheick P O Sangaré; Ogobara Doumbo; Jacques Le Bras
Journal:  Int J Parasitol       Date:  2008-01-03       Impact factor: 3.981

6.  Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies.

Authors:  Moe Kyaw Myint; Charlotte Rasmussen; Aung Thi; Dorina Bustos; Pascal Ringwald; Khin Lin
Journal:  Malar J       Date:  2017-04-07       Impact factor: 2.979

7.  Identifying Recrudescent Plasmodium falciparum in Treated Malaria Patients by Real-time PCR and High Resolution Melt Analysis of Genetic Diversity.

Authors:  Khalid B Beshir; Nouhoum Diallo; Colin J Sutherland
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

8.  Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali.

Authors:  Mamadou Tekete; Abdoulaye A Djimde; Abdoul H Beavogui; Hamma Maiga; Issaka Sagara; Bakary Fofana; Dinkorma Ouologuem; Souleymane Dama; Aminatou Kone; Demba Dembele; Mamadou Wele; Alassane Dicko; Ogobara K Doumbo
Journal:  Malar J       Date:  2009-02-26       Impact factor: 2.979

9.  Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.

Authors:  Patrick Sawa; Seif A Shekalaghe; Chris J Drakeley; Colin J Sutherland; Collins K Mweresa; Amrish Y Baidjoe; Alphaxard Manjurano; Reginald A Kavishe; Khalid B Beshir; Rahma U Yussuf; Sabah A Omar; Cornelus C Hermsen; Lucy Okell; Henk D F H Schallig; Robert W Sauerwein; Rachel L Hallett; Teun Bousema
Journal:  J Infect Dis       Date:  2013-03-06       Impact factor: 5.226

10.  In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique.

Authors:  Abel Nhama; Quique Bassat; Sónia Enosse; Arsenio Nhacolo; Rosália Mutemba; Eva Carvalho; Eva Naueia; Esperança Sevene; Caterina Guinovart; Marian Warsame; Sergi Sanz; Abdul Mussa; Graça Matsinhe; Pedro Alonso; Armindo Tiago; Eusebio Macete
Journal:  Malar J       Date:  2014-08-10       Impact factor: 2.979
View more
  1 in total

1.  Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali.

Authors:  Hamma Maiga; Anastasia Grivoyannis; Issaka Sagara; Karim Traore; Oumar B Traore; Youssouf Tolo; Aliou Traore; Amadou Bamadio; Zoumana I Traore; Kassim Sanogo; Ogobara K Doumbo; Christopher V Plowe; Abdoulaye A Djimde
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.